Pages that link to "Q53599930"
Jump to navigation
Jump to search
The following pages link to The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density. (Q53599930):
Displaying 31 items.
- Bone repair with skeletal stem cells: rationale, progress to date and clinical application (Q26744340) (← links)
- Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges (Q26744599) (← links)
- Sclerostin Inhibition in the Management of Osteoporosis (Q26750713) (← links)
- From disease to treatment: from rare skeletal disorders to treatments for osteoporosis (Q26764854) (← links)
- Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis (Q27022580) (← links)
- Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease. (Q30234751) (← links)
- Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis (Q35507830) (← links)
- Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys (Q36198506) (← links)
- CORR Insights(®): Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? (Q36746795) (← links)
- New horizons in treatment of osteoporosis. (Q37630995) (← links)
- New anabolic therapies for osteoporosis (Q38646406) (← links)
- Role and mechanism of action of sclerostin in bone (Q38807230) (← links)
- Exploiting the WNT Signaling Pathway for Clinical Purposes (Q39255803) (← links)
- Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential (Q42364116) (← links)
- Osteoporosis treatment: bisphosphonates reign to continue for a few more years, at least? (Q43573918) (← links)
- Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease. (Q46114833) (← links)
- Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model (Q47099469) (← links)
- Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review (Q47400369) (← links)
- Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab (Q48088703) (← links)
- Application of anti-Sclerostin therapy in non-osteoporosis disease models (Q51363424) (← links)
- Anabolic Therapy for the Treatment of Osteoporosis in Childhood (Q51733584) (← links)
- Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl/+ osteogenesis imperfecta mouse model. (Q52653933) (← links)
- N-cadherin Regulation of Bone Growth and Homeostasis Is Osteolineage Stage-Specific. (Q52786325) (← links)
- Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy (Q58566593) (← links)
- The Emerging Role of Osteocytes in Cancer in Bone (Q64096227) (← links)
- Sclerostin and Its Associations With Bone Metabolism Markers and Sex Hormones in Healthy Community-Dwelling Elderly Individuals and Adolescents (Q89967626) (← links)
- Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development (Q90729095) (← links)
- Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway (Q91289594) (← links)
- Pharmacological Therapy of Osteoporosis: What's New? (Q91788816) (← links)
- Romosozumab: a novel bone anabolic treatment option for osteoporosis? (Q92137168) (← links)
- Osteogenesis Imperfecta: New Perspectives From Clinical and Translational Research (Q93110748) (← links)